Blood glucose sensors for continuous interstitial glucose monitoring are reimbursed in Belgium for certain categories of type 2 diabetics treated with basal-prandial insulin regimens under the Diabetes Convention. They provide a better assessment of glycemic exposure, allowing finer tuning of insulin doses and adjustment of non-insulin glucose-lowering medications. As with type 1 diabetes, their use requires reevaluation of dietary practices and guided dietary counseling based on ambulatory measurements as a result of improved assessment of glycemic exposure, including postprandial excursions and nocturnal glucose.
Keywords
Type 2 diabetes, continuous glucose monitoring, HbA1c, time in range